apap dla dzieci forte smak pomarańczowy 40 mg/ml zawiesina doustna
us pharmacia sp. z o.o. - paracetamolum - zawiesina doustna - 40 mg/ml
gripex control duo 500 mg + 65 mg tabletki powlekane
us pharmacia sp. z o.o. - paracetamolum + coffeinum - tabletki powlekane - 500 mg + 65 mg
paracetamol medicinae 500 mg tabletki
medicinae sp. z o.o. - paracetamolum - tabletki - 500 mg
paracetamolum farmalider 1000 mg tabletki
farmalider sa - paracetamolum - tabletki - 1000 mg
gripex duo 500 mg + 6,1 mg tabletki powlekane
us pharmacia sp. z o.o. - paracetamolum + phenylephrini hydrochloridum - tabletki powlekane - 500 mg + 6,1 mg
apap przeziębienie max 1000 mg + 50 mg + 12,2 mg/sasz. proszek do sporządzania roztworu doustnego w saszetce
us pharmacia sp. z o.o. - paracetamolum + coffeinum + phenylephrini hydrochloridum - proszek do sporządzania roztworu doustnego w saszetce - 1000 mg + 50 mg + 12,2 mg/sasz.
gripex hot intense 1000 mg + 50 mg + 12,2 mg proszek do sporządzania roztworu doustnego w saszetce
us pharmacia sp. z o.o. - paracetamolum + coffeinum + phenylephrini hydrochloridum - proszek do sporządzania roztworu doustnego w saszetce - 1000 mg + 50 mg + 12,2 mg
vianib 100 mg kapsułki twarde
vianex s.a. - imatinibi mesilas - kapsułki twarde - 100 mg
vianib 400 mg kapsułki twarde
vianex s.a. - imatinibi mesilas - kapsułki twarde - 400 mg
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.